Market Cap
Stock Chart
Pharmaxis - 30 day Poll
Recent BLOGS About Pharmaxis Add New
Pharmaxis trading halt & 40% stock price drop
Pharmaxis is in a trading halt as of today. Does anyone know why? Read more
|
Pharmaxis has started to move up
Pharmaxis has started to move up – is this in relation to their expected cystic fibrosis phase II … Read more
|
Pharmaxis approaching new milestones
Pharmaxis getting closer to further achievements which provides an incentive to purchase and hold fo… Read more
|
Pharmaxis has begun its run up again?
Has Pharmaxis has begun its run up again with Aust. approval soon for bronchetasis & cystic fibr… Read more
|
Latest Company News
|
Pharmaxis Announces Agreement for European Marketing of Bronchitol
irasia.com - Aug 31, 2010 Pharmaceutical company Pharmaxis (ASX:PXS) today announced it has finalised a strategic marketing and sales service agreement for the commercialisation of Bronchitol for cystic fibrosis in Europe ...
|
|
Quarterly Report to Shareholders and Investor Conference Call
irasia.com - Jul 20, 2010 DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages ...
|
|
Update on Pharmaxis Chief Executive Officer
irasia.com - Jul 9, 2010 The Chairman of the Pharmaxis Ltd Board, Mr Denis Hanley advises that Pharmaxis Chief Executive Officer, Dr Alan Robertson, continues to recover after undergoing a medical procedure three weeks ...
|
|
Market Wrap: Aus shares close weaker
Finance News Network - Jun 23, 2010 Poor US housing data sent Aussie shares sliding today, prompting the local share market to close lower as investors sold off banking and mining stocks. Westpac and the Commonwealth Bank led the ...
|
|
Pharmaxis shares dive 30% on trial results
CFO World - Jun 23, 2010 By CFO World Staff (CFO World) Pharmaceutical company, Pharmaxis (ASX:PXS) underwhelmed the market with the results from their phase III clinical trial of cystic fibrosis treatment drug Bronchitol ...
|
|
Pharmaxis Ltd. Announces Results For Second Phase III Trial Of Bronchitol In Cystic Fibrosis
Reuters Key Development - Jun 22, 2010 |
|
Pharmaxis Ltd.'s CEO To Undergone Medical Procedure; Will Be Absent From Office For Next Few Weeks
Reuters Key Development - Jun 18, 2010 |
Website
Videos related to Pharmaxis
Company Profile
Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases.
The company's first product, Aridol, is now registered for sale in Australia, Europe and South East Asia and a request for marketing approval has been filed in the United States. Aridol is designed to assist in the management of both asthma and chronic obstructive pulmonary disease.
The Company's second product, Bronchitol, has completed the first regulatory Phase 3 trials in both cystic fibrosis and bronchiectasis. Bronchitol is designed to restore normal lung hydration, improve lung function and to help relieve the mucus burden in the lungs of patients suffering from chronic respiratory conditions.
The company's other application area is chronic obstructive pulmonary disease (COPD) and is the largest market opportunity. COPD is a lung disease that makes it hard to breathe. It is caused by damage to the lungs over many years, usually from smoking. COPD includes Chronic bronchitis and Emphysema
Cash & Cash Equivalents at end of 1st Jul 2010: $86M.
Some Previous & Current Institutional Investors: ANZ Nominees Limited, JP Morgan Nominees Australia Limited, Citicorp Nominees Pty Limite, CM Capital
Possible Competition & Similar Companies:
Vertex Pharmaceuticals for Cystic Fibrosis (San Diego)
- click here to see on our USA sister website, USA site requires separate log-in
Upcoming Events:
Jul-Sep 2010, Pharmaxis will now move forward to meet the U.S. Food & Drug Administration (FDA) to discuss a New Drug Application (NDA) for Bronchitol.
Sep-Dec 2010 Submission to the European regulatory authority (EMA) of further the safety data from CF302 to receive a decision later this year for Bronchitol - Cystic Fibrosis.
Also possible in the coming months:
PXS25 starts Phase 1A clinical trial



